Delivery Order SPE2DB25D3012-SPE2DB25FWXBN

Award Date 4/28/25
Potential Completion Date 5/19/25
Potential Value $60K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of OCREVUS 300 MG/10 ML VIAL 10ML. The contract has a ceiling value of $34,955.36 and runs through April 2, 2025. The contract is a firm fixed-price, delivery order contract with no set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product, with a ceiling value of $46,236.16 and a performance period through April 3, 2024. Amerisourcebergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) with DLA, valued at up to...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a pharmaceutical product, at a firm fixed price. The contract has a ceiling value of $120,192.80 and a completion date of May 20, 2025. This award is not set aside and represents an open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp. The contract is for the supply of OCREVUS 300 mg/10 ml vials, a specialty medication. The contract has a ceiling value of $23,118.08 and runs through November 4, 2024. AmerisourceBergen, a major pharmaceutical distributor, leverages its extensive supply chain to provide a wide range of medical products to various government agencies, including the military. The company holds...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of OCREVUS 300 mg/10 ml vials. The contract has a ceiling value of $69,354.24 and a completion date of August 9, 2024. It is a firm fixed-price delivery order contract, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of OCREVUS 300 mg/10 ml vials, with a ceiling value of $36,057.84 and a performance period through March 11, 2025. The contract is not designated as a set-aside and is a firm-fixed price delivery order. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract has a firm fixed price ceiling value of $36,057.84 and a period of performance through April 18, 2025. This award is associated with a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $115,590.40 fixed-price contract is for the supply of OCREVUS 300 mg/10 ml vials, a specialty medication. The contract has a ceiling value of $115,590.40 and an ultimate completion date of September 3, 2024. This order is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication, with a ceiling value of $120,192.80. The contract is a Firm Fixed Price Delivery Order that runs through April 14, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) the company holds with the DLA Troop Support...
The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor, for the supply of 4564617533 ! OCREVUS 300 MG/10 ML VIAL 10ML. The delivery order, valued at $23,118.08, is a firm fixed price contract with a completion date of June 6, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued up to $999,999,999.00 and...
  • SPE2DB25D3012
    Indefinite Delivery Contract
  • SPE2DB25D3012-SPE2DB25FWXBN
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a medication, with a ceiling value of $60,096.40 and a period of performance through May 19, 2025. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which serves as a comprehensive global pharmaceutical support vehicle with a performance period through December 2026. This delivery order is not designated as a set-aside contract.

Generated 7/28/25, 11:05 AM